Results · Apr-Jun 2026
Senores Pharmaceuticals Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 31% to ₹180 crore from ₹138 crore in Apr-Jun 2025.
Operating profit grew 57% to ₹53.8 crore, an operating margin of 29.8% (up 5.1 points from a year ago).
Net profit grew 44% to ₹30.5 crore from ₹21.2 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +3%, net profit −17%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 180.2 | 138.0 | +31% |
| Operating profit (EBITDA) | 53.8 | 34.2 | +57% |
| Operating margin | 29.8% | 24.8% | +5.1 pts |
| Net profit | 30.5 | 21.2 | +44% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.